益脾养肝方对大鼠肝癌前病变病理形态和脾脏T细胞亚群的影响

Compound Yipi Yanggan Fang Inhibits Liver Precancerous Lesion and Influences T Cell Subsets of Spleen

目的:观察益脾养肝方对二乙基亚硝胺(DEN)诱导的大鼠肝癌癌前病变病理形态和脾脏T细胞亚群的影响。方法:将80只大鼠随机分为空白组、模型组、益脾养肝方大、小剂量组,腹腔注射DEN制备肝癌癌前病变模型,16周后处死大鼠,检测肝功能、肝组织病理变化,脾脏组织免疫荧光染色观察CD3+、CD4+和CD8+T细胞表达情况。结果:与模型组比较,益脾养肝方小、大剂量均能显著降低ALT、AST、ALP水平,且益脾养肝方大剂量组疗效更好(P<0.01);肝组织HE、Masson染色病理切片显示,益脾养肝方大、小剂量组大鼠肝癌前病变病理形态明显改善;脾脏组织免疫荧光染色结果显示,益脾养肝方可提高CD3+、CD4+T细胞数量,降低CD8+T细胞数量。结论:益脾养肝方对大鼠肝癌前病变进展具有抑制作用,其作用机理可能是通过调节机体的免疫功能抑制肝癌形成。

Objective： To observe the effect of compound yipi yanggan Fang（ YPYGF） on liver precancerous lesion and T cell subsets of spleen in rats. Methods： Totally 80 rats were randomly divided into the normal control group,the DENa group,and two YPYGF（ 0. 5 and 1.0 g/ml） treatment groups. After 16 weeks of administration,rats were sacrificed to messure the changes of liver function,liver tissue and T cell subpopulations in rat spleen sections. Results： Compared with the DEN group,the serum levels of ALT,AST,ALP in YPYGF groups were significantly lower,the effect of high-dose group was better（ P 0. 01）. HE and Masson staining pathological sections showed that compound yipi yanggan Fang could improve the pathological changes and change the expression of T cell subsets in spleen in the process of liver precancerous lesions. Conclusion： Compound yipi yanggan Fang could mediate immune function of organism to inhibit the progression of liver precancerous lesions in rats.